ResearcherUniversity of Tennessee Health Science CenterNo recent work listed
Sonam Kumari
Matched on ORCID iD 0000-0002-6052-9972; OpenAlex author ID A5103860104. Sources: OpenAlex.
Their work
- Papers
- 10
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 10
- Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Co-author DOI 10.1038/s42003-022-04102-4↗
- Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Co-author DOI 10.3390/biomedicines9121814↗
- Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Co-author DOI 10.1038/s41416-019-0629-9↗
- Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2019.04.005↗
- Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Co-author DOI 10.1016/j.nano.2019.102027↗
- Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Co-author DOI 10.1186/s13046-018-1009-7↗
- Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Co-author DOI 10.3390/cells9010103↗
- Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics11110574↗
- MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Co-author DOI 10.1038/s41389-018-0031-0↗
- MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1038/onc.2016.218↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Meena Jaggi · 10 shared papers, 2017–2022 · strength 0.98
- Paper Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. DOI 10.3390/biomedicines9121814↗
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. DOI 10.1038/s41416-019-0629-9↗
- Murali Mohan Yallapu · 10 shared papers, 2017–2022 · strength 0.98
- Paper Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. DOI 10.3390/biomedicines9121814↗
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. DOI 10.1038/s41416-019-0629-9↗
- Subhash C. Chauhan · 10 shared papers, 2017–2022 · strength 0.98
- Paper Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. DOI 10.3390/biomedicines9121814↗
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. DOI 10.1038/s41416-019-0629-9↗
- Sheema Khan · 8 shared papers, 2017–2022 · strength 0.78
- Paper Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. DOI 10.3390/biomedicines9121814↗
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. DOI 10.1038/s41416-019-0629-9↗
- Bilal Bin Hafeez · 6 shared papers, 2017–2022 · strength 0.56
- Paper Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. DOI 10.3390/biomedicines9121814↗
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Mohammed Sikander · 5 shared papers, 2017–2022 · strength 0.49
- Paper Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. DOI 10.3390/biomedicines9121814↗
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pa… DOI 10.3390/cells9010103↗
- Vivek Kumar Kashyap · 4 shared papers, 2018–2022 · strength 0.38
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. DOI 10.1038/s41389-018-0031-0↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Stephen W. Behrman · 4 shared papers, 2017–2022 · strength 0.38
- Paper Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. DOI 10.1038/s42003-022-04102-4↗
- Paper Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. DOI 10.1038/s41416-019-0629-9↗
- Paper Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. DOI 10.1016/j.biomaterials.2019.04.005↗
- Saini Setua · 4 shared papers, 2019 · strength 0.36
- Paper Gemcitabine Combination Nano Therapies for Pancreatic Cancer. DOI 10.3390/pharmaceutics11110574↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Paper Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. DOI 10.1186/s13046-018-1009-7↗
- Neeraj Chauhan · 3 shared papers, 2019 · strength 0.26
- Paper Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pa… DOI 10.3390/cells9010103↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Paper Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. DOI 10.1186/s13046-018-1009-7↗
- Andrew E. Massey · 2 shared papers, 2019 · strength 0.17
- Mehdi Chaib · 1 shared paper, 2022 · strength 0.13
- Kamalika Samanta · 1 shared paper, 2019 · strength 0.11
- Subash C. Gupta · 1 shared paper, 2018 · strength 0.09
- Fathi T. Halaweish · 1 shared paper, 2019 · strength 0.09
- Advait B. Shetty · 1 shared paper, 2019 · strength 0.08
- Wěi Li · 1 shared paper, 2019 · strength 0.08
- Zachary E. Stiles · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.